The predictive value of eIF2α-P for Trastuzumab therapeutic response in HER2+ breast cancer may justify clinical trials to determine the therapeutic utility of SAL003 and possibly other eIF2α-phosphatase inhibitors for sustained induction of eIF2α-P in combination with Trastuzumab-based therapies. Here, ERBB2 is linked to breast carcinoma.